false --12-31 2026 Q2 0001412126 0001412126 2026-01-01 2026-06-30 0001412126 2026-06-30 0001412126 2025-12-31 0001412126 us-gaap:SeriesAPreferredStockMember 2026-06-30 0001412126 us-gaap:SeriesAPreferredStockMember 2025-12-31 0001412126 us-gaap:SeriesBPreferredStockMember 2026-06-30 0001412126 us-gaap:SeriesBPreferredStockMember 2025-12-31 0001412126 us-gaap:SeriesCPreferredStockMember 2026-06-30 0001412126 us-gaap:SeriesCPreferredStockMember 2025-12-31 0001412126 2025-01-01 2025-06-30 0001412126 us-gaap:CommonStockMember 2025-12-31 0001412126 RMSL:SeriesAPreferredStocksMember 2025-12-31 0001412126 RMSL:SeriesBPreferredStocksMember 2025-12-31 0001412126 RMSL:SeriesCPreferredStocksMember 2025-12-31 0001412126 RMSL:DiscountToCommonStockMember 2025-12-31 0001412126 us-gaap:AdditionalPaidInCapitalMember 2025-12-31 0001412126 us-gaap:RetainedEarningsMember 2025-12-31 0001412126 us-gaap:CommonStockMember 2026-01-01 2026-06-30 0001412126 RMSL:SeriesAPreferredStocksMember 2026-01-01 2026-06-30 0001412126 RMSL:SeriesBPreferredStocksMember 2026-01-01 2026-06-30 0001412126 RMSL:SeriesCPreferredStocksMember 2026-01-01 2026-06-30 0001412126 RMSL:DiscountToCommonStockMember 2026-01-01 2026-06-30 0001412126 us-gaap:AdditionalPaidInCapitalMember 2026-01-01 2026-06-30 0001412126 us-gaap:RetainedEarningsMember 2026-01-01 2026-06-30 0001412126 us-gaap:CommonStockMember 2026-06-30 0001412126 RMSL:SeriesAPreferredStocksMember 2026-06-30 0001412126 RMSL:SeriesBPreferredStocksMember 2026-06-30 0001412126 RMSL:SeriesCPreferredStocksMember 2026-06-30 0001412126 RMSL:DiscountToCommonStockMember 2026-06-30 0001412126 us-gaap:AdditionalPaidInCapitalMember 2026-06-30 0001412126 us-gaap:RetainedEarningsMember 2026-06-30 0001412126 2026-04-01 2026-06-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure RMSL:Integer

Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 10-Q

 

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended June 30, 2026

 

or

 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from April 1, 2026 to June 30, 2026

 

Commission File Number: 000-53450

 

REMSLEEP HOLDINGS, INC.

(Exact name of registrant as specified in its charter)

 

Nevada   47-5386867
(State or other jurisdiction of incorporation or organization)   (I.R.S. Employer Identification No.)

 

500 S Australian Ave, West Palm Beach FL 3341

(Address of principal executive offices) (Zip Code)

 

561-668-0846

(Registrant’s telephone number, including area code)

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer Accelerated filer
Non-accelerated filer Smaller reporting company
Emerging growth company  

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No 

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, $0.001 par value   RMSL   OTCPink

 

Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of June 30, 2026 there were 1,739,610,123 shares of common stock outstanding.

 

 

   

 

 

TABLE OF CONTENTS

 

    Page No.
     
  PART I - FINANCIAL INFORMATION 3
   
Item 1. Financial Statements 3
     
Item 2. Management’s Discussion and Analysis of Financial Condition and Plan of Operations 13
     
Item 3. Quantitative and Qualitative Disclosures About Market Risk 16
     
Item 4. Controls and Procedures 16
     
  PART II - OTHER INFORMATION 17
   
Item 1. Legal Proceedings 17
     
Item 1A. Risk Factors 17
     
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 17
     
Item 3. Defaults Upon Senior Securities 17
     
Item 4. Mine Safety Disclosures 17
     
Item 5. Other Information 17
     
Item 6. Exhibits 17
     
Signatures 18

 

 

 

 

 2 

 

 

PART I - FINANCIAL INFORMATION

 

ITEM 1. FINANCIAL STATEMENTS

 

REMSLEEP HOLDINGS, INC.

Balance Sheet

As at June 30, 2026

(Unaudited)

            
   Notes  As at
June 30,
2026
(Unaudited)
   As at
December 31,
2025
(Unaudited)
 
      ($) 
ASSETS             
Current Assets             
Cash and cash equivalents  4       214,514 
Inventory  5   69,456    46,304 
Other assets  6   9,844    4,375 
Total Current Assets      79,300    265,193 
Other assets      10,000    10,000 
Right of use assets      26,207    26,207 
Property and equipment, net      38,356    38,356 
Total Assets      153,863    339,756 
              
EQUITY & LIABILITIES             
Current Liabilities             
Bank overdraft      88,443     
Accounts payable  7   149,189    114,761 
Accrued compensation  8   72,680    46,000 
Convertible notes payable  9   14,146    52,199 
Derivative liability  10   47,429    63,920 
Convertible notes - interest accrued      8,293    4,607 
Operating lease liability – current portion      17,213    18,154 
Total Current Liabilities      397,393    299,641 
Convertible notes  11   35,000     
Operating lease liability – net of current portion      2,398    8,053 
Total Liabilities      434,791    307,694 
SHAREHOLDERS’ EQUITY             
Common stock, $0.001 par value, 3,000,000,000 shares authorized, 1,739,610,123 and 1,659,190,126 shares issued and outstanding, respectively      1,739,609    1,659,189 
Series A preferred stock, $0.001 par value, 5,000,000 shares authorized, 5,000,000 and issued and outstanding      5,000    5,000 
Series B preferred stock, $0.001 par value, 5,000,000 shares authorized, 500,000 shares issued and outstanding      500    500 
Series C preferred stock, $0.001 par value, 5,000,000 shares authorized, 4,000,000 issued and outstanding      4,000    4,000 
Discount to common stock      (94,708)   (94,708)
Additional paid in capital      16,749,137    16,749,137 
Accumulated deficit      (18,684,466)   (18,291,056)
Total Shareholders’ Equity      (280,928)   32,062 
Total Liabilities and Shareholders’ Equity      153,863    339,756 

 

The accompanying notes are an integral part of these financial statements.

 

 

 

 3 

 

 

REMSLEEP HOLDINGS, INC.

Statement of Operations

For the period ended June 30, 2026

            
   Notes  For the
six months ended
June 30, 2026
   For the
six months ended
June 30, 2025
 
      (Amounts in $) 
Revenue          4,824 
Cost of goods sold          (600
Gross margin          4,224 
              
Operating expenses             
Professional fees      (8,580)   (35,550)
Compensation expenses      (29,700)   (51,000)
Development expenses          (18,700)
Lease expense      (6,200)   (26,491)
General and administrative expenses      (223,138)   (136,350)
Income / (Loss) from operations      (267,618)   (263,867)
              
Other Income / (expense)             
Interest expense      (83,965)   (219,967)
Loss on issuance of convertible debt      (94,454)   (118,654)
Gain/(loss) on conversion of debt      36,136    (54,133
Changes in fair value of derivative      16,491    283,361 
Net Profit / (loss) before provision for Income taxes      (393,410)   (373,260)
              
Provision for income tax           
Net Profit / (loss)      (393,410)   (373,260)

 

The accompanying notes are an integral part of these financial statements.

 

 

 

 

 4 

 

 

REMSLEEP HOLDINGS, INC.

Statement of Shareholders’ Equity

As at June 30, 2026

(Unaudited)

                                             
   Common Stock   Preferred Stock A   Preferred Stock B   Preferred Stock C   Discount to Common   Additional Paid in   Accumulated Profit/      
   Shares  Amount ($)   Shares  Amount ($)   Shares  Amount ($)   Shares  Amount ($)  

Stock

($)

  

Capital

($)

  

(Deficit)

($)

  

Total

($)

 
As at January 1, 2026 (Unaudited)  1,659,190,126  1,659,189   5,000,000  5,000   500,000  500   4,000,000  4,000   (94,708)  16,749,137   (18,291,056)  32,062 
Profit / (loss) for the period                            (393,410)  (393,410)
Capital issued  80,419,997  80,420                           80,420 
As at June 30, 2026 (Unaudited)  1,739,610,123  1,739,609   5,000,000  5,000   500,000  500   4,000,000  4,000   (94,708)  16,749,137   (18,684,466)  (280,928)

 

The accompanying notes are an integral part of these financial statements.

 

 

 

 

 5 

 

 

REMSLEEP HOLDINGS, INC.

Statement of Cashflows

As at June 30, 2026

(Unaudited)

             
   For the six months ended June 30,  
   2026    2025  
   (amounts in $)  
Cash flow from operating activities             
(Loss) / profit before income tax   (393,410)     (373,260 )
Adjustment for non cash charges and other items:             
Depreciation / amortization         14,227  
Change in fair value of derivatives   (16,491)     (283,361 )
Loss on issuance of convertible debt         118,654  
Loss on conversion of debt         54,133  
Operating lease expense         207,752  
Bad debt expense         7,017  
Changes in working capital          2,741  
Decrease / (increase) in inventory   (23,152)     (19,835 )
Decrease / (increase) in deposit on inventory         9,050  
Decrease / (increase) in prepaid and other assets   (5,469)     15,300  
(Decrease) / increase in accounts payable   34,428      (16,000 )
(Decrease) / increase in accrued compensation   26,680       
(Decrease) / increase in notes payable   (38,053)      
(Decrease) / increase in accrued interest   (9,506)     12,214  
(Decrease) / increase in Derivative liability   6,596       
Cash flow from operating activities   (418,377)     (251,368 )
              
Cash flow from investing activities             
Additions in fixed assets          
Cash flow from / (used) in investing activities          
              
Cash flow from financing activities             
Proceeds from convertible note payable   35,000      204,000  
Bank overdraft   88,443       
Common stock issued during the year   80,420       
Cash flow from financing activities   203,863      204,000  
              
Increase / (decrease) in cash and cash equivalents   (214,514)     (47,368 )
Cash and cash equivalents at beginning of the year   214,514      463,343  
Cash and cash equivalents at end of the year         415,975  

 

The accompanying notes are an integral part of these financial statements.

 

 

 

 6 

 

 

REMSLEEP HOLDINGS, INC.

Notes to the Financial Statements

For the six months ended June 30, 2026

 

 

1 LEGAL STATUS AND OPERATIONS
   
  REMSleep Holdings, Inc., (the “Company”) was incorporated in the State of Nevada on June 6, 2007. On January 5, 2015 the name of the Company was changed to REMSleep Holdings, Inc. and the business model was changed to reflect the new direction of the Company; to develop and distribute products to help people affected by sleep apnea. On May 30, 2015, REMSleep LLC was formally merged into REMSleep Holdings, Inc.

 

2 BASIS OF PREPARATION

 

2.1 Statement of compliance
   
  These unaudited financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”) and the rules and regulations of the Securities and Exchange Commission (“SEC”). These financial statements and the notes attached hereto should be read in conjunction with the financial statements and notes included in the Company’s 10-K for its fiscal year ended December 31, 2025. In the opinion of the Company, all adjustments, including normal recurring adjustments necessary to present fairly the financial position of the Company, as of June 30, 2026, and the results of its operations and cash flows for the six months then ended have been included. The results of operations for the interim period are not necessarily indicative of the results for the full year ending December 31, 2026.

 

2.2 Accounting Convention
   
  These financial statements have been prepared on the basis of ‘historical cost convention using accrual basis of accounting except as otherwise stated in the respective accounting policies notes.
 
  Going concern
 
  The Company had accumulated losses and had a negative cash flow from operations for the reporting period. Further, the accumulated (deficit) has raised at that date, which raises substantial doubt about its ability to continue as a going concern. The future of the Company is dependent upon its ability to obtain financing and upon future profitable operations from development of its natural properties. Management has plans to seek additional capital through private placement and public offering of its common stock. The financial statements don’t contain any adjustments relating to recoverability and classification of its recorded assets, or the amounts of and classification of its liabilities that might be necessary in the event the Company cannot continue to exist.

 

2.3 Critical accounting estimates and judgements
   
  The preparation of financial statements in conformity with the approved accounting standards require management to make judgements, estimates and assumptions that affect the application of policies and reported amounts of assets and liabilities, income and expenses. The estimates and associated assumptions are based on historical experience and various other factors that are believed to be reasonable under the circumstances, the results of which form the basis of making the judgments about carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates.
   
  The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimates are revised if the revision affects only that period, or in the period of the revision and future periods.
   

 

 

 7 

 

 

  The areas involving higher degree of judgment and complexity, or areas where assumptions and estimates made by the management are significant to the financial statements are as follows:
     
  i) Equipment - estimated useful life of equipment (note - 3.7)
  ii) Exploration and evaluation cost (note - 3.4)
  iii) Provision for doubtful debts (note - 3.4)
  iv) Provision for income tax (note - 3.1)

 

3 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

3.1 Income tax
   
  The tax expense for the year comprises of income tax, and is recognized in the statement of earnings. The income tax charge is calculated on the basis of the tax laws enacted or substantively enacted at the balance sheet date. Management periodically evaluates positions taken in tax returns with respect to situations in which applicable tax regulation is subject to interpretation and establishes provisions where appropriate on the basis of amounts expected to be paid to the tax authorities.
   
  Deferred income tax is accounted for using the balance sheet liability method in respect of all temporary differences arising from differences between the carrying amount of assets and liabilities in the financial statements and the corresponding tax bases used in the computation of taxable profit. Deferred income tax liabilities are recognised for all taxable temporary differences and deferred income tax assets are recognised to the extent that it is probable that taxable profits will be available against which the deductible temporary differences and unused tax losses can be utilized. Deferred income tax is calculated at the rates that are expected to apply to the period when the differences are expected to be reversed.

 

3.2 Trade and other payables
   
  Liabilities for trade and other amounts payable are carried at cost, which is the fair value of the consideration to be paid in future for goods and services received, whether or not billed to the Company.

 

3.3 Provisions
   
  A provision is recognized in the financial statements when the Company has a legal or constructive obligation as a result of past events and it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of obligation.

 

3.4 Accounts Receivable
   
  Accounts receivable are non-interest bearing obligations due under normal course of business. The management reviews accounts receivable on a monthly basis to determine if any receivables will be potentially uncollectible. Historical bad debts and current economic trends are used in evaluating the allowance for doubtful accounts. The Company includes any accounts receivable balances that are determined to be uncollectible in its overall allowance for doubtful accounts. After all attempts to collect a receivable have failed, the receivable is written off against the allowance. Based on the information available, the Company believes its allowance for doubtful accounts as of period ended is adequate.

 

 

 

 8 

 

 

 

3.5 Contingent liabilities
   
  A contingent liability is disclosed when the Company has a possible obligation as a result of past events, the existence of which will be confirmed only by the occurrence or non-occurrence, of one or more uncertain future events, not wholly within the control of the Company; or when the Company has a present legal or constructive obligation, that arises from past events, but it is not probable that an outflow of resources embodying economic benefits will be required to settle the obligation, or the amount of the obligation cannot be measured with sufficient reliability.

 

3.6 Financial liabilities
   
  Financial liabilities are recognized when the Company becomes party to the contractual provision of the instruments and the Company loses control of the contractual right that comprise the financial liability when the obligation specified in the contract is discharged, cancelled or expired. The Company classifies its financial liabilities in two categories: at fair value through profit or loss and financial liabilities measured at amortized cost. The classification depends on the purpose for which the financial liabilities were incurred. Management determines the classification of its financial liabilities at initial recognition.

 

  (a) Financial liabilities at fair value through profit or loss
     
    Financial liabilities at fair value through profit or loss are financial liabilities held for trading. A financial liability is classified in this category if incurred principally for the purpose of trading or payment in the short-term. Derivatives (if any) are also categorized as held for trading unless they are designated as hedges.
     
  (b) Financial liabilities measured at amortized cost
     
    These are non-derivative financial liabilities with fixed or determinable payments that are not quoted in an active market. These are recognized initially at fair value, net of transaction costs incurred and are subsequently stated at amortized cost; any difference between the proceeds (net of transaction costs) and the redemption value is recognized in the profit and loss account.

 

 

 

 9 

 

 

3.7 Property, plant and equipment
     
  All equipments are stated at cost less accumulated depreciation and impairment loss. The cost of fixed assets includes its purchase price, import duties and non-refundable purchase taxes and any directly attributable costs of bringing the asset to its working condition and location for its intended use.
     
  Depreciation on additions to property, plant and equipment is charged, using straight line method, on pro rata basis from the month in which the relevant asset is acquired or capitalized, up to the month in which the asset is disposed off. Impairment loss, if any, or its reversal, is also charged to income for the year. Where an impairment loss is recognized, the depreciation charge is adjusted in future periods to allocate the asset’s revised carrying amount, less its residual value, over its estimated useful life.
     
  Maintenance and normal repair costs are expensed out as and when incurred. Major renewals and improvements are capitalized and assets so replaced, if any are retired.
   
  Gains and losses on disposal of fixed assets, if any, are recognized in statement of profit and loss.

 

3.8 Cash and cash equivalents
     
  Cash and cash equivalents include cash in hand and deposits held at call with banks. For the purpose of the statement of cash flows, cash and cash equivalents bank balances and short term highly liquid investments subject to an insignificant risk of changes in value and with maturities of less than three months.

 

3.9 Revenue recognition
   
  Revenue is recognised to the extent it is probable that the economic benefits will flow to the Company and the revenue can be measured reliably. Revenue is measured at the fair value of the consideration received or receivable for goods sold or services rendered, net of discounts and sales tax and is recognised when significant risks and rewards are transferred.

 

3.10 Functional and presentation currency
   
  Items included in the financial statements are measured using the currency of the primary economic environment in which the Company operates. The financial statements are presented in US (Dollars) which is the Company’s presentation currency. All financial information presented in US Dollars has been rounded to the nearest dollar unless otherwise stated.

 

3.11 Foreign currency transactions
   
  Foreign currency transactions are translated into the functional currency using the exchange rate prevailing on the date of the transaction. Monetary assets and liabilities denominated in foreign currencies are translated into functional currency using the exchange rate prevailing at the statement of financial position date. Foreign exchange gains and losses resulting from the settlement of such transactions and from the translation at year-end exchange rates are recognized in the profit and loss account.

 

 

 

 10 

 

 

3.12 Contingencies
   
  The assessment of the contingencies inherently involves the exercise of significant judgment as the outcome of the future events cannot be predicted with certainty. The Company, based on the availability of the latest information, estimates the value of contingent assets and liabilities, which may differ on the occurrence / non-occurrence of the uncertain future event(s).

 

4 Cash
   
  This represent cash in hand and cash deposited in bank accounts (current) by the Company.

 

5 Inventory        

     
Opening balance  $46,304 
Net movement during the period   23,152 
   $69,456 

 

6 Other assets        

     
Opening balance  $4,375 
Net movement during the period   5,469 
   $9,844 

 

7 Accounts payable        

     
Opening balance  $114,761 
Net movement in liabilities during the period   34,428 
   $149,189 

 

8 Accrued compensation        

     
Opening balance  $46,000 
Net movement in liabilities during the period   26,680 
   $72,680 

 

9 Convertible notes payable        

     
Opening balance  $52,199 
Net movement in liabilities during the period   (38,053)
   $14,146 

 

 

 

 11 

 

 

10 Derivative liability        

     
Opening balance  $63,920 
Net movement in liabilities during the period   (16,491)
   $47,429 

 

11 Convertible notes        

     
Outstanding balance  $35,000 

 

12 Share Capital
   
  This represents ordinary share capital issued by the Company at the par value. The shares issued by the company, if any, during the period are represented in statement of changes in equity.

 

13 Contingencies and Commitments
   
  The company has no contingency and commitment as at the end of reporting period.

 

14 Other Information
   
  i) Evaluation of Disclosure Controls and Procedures
   
  Management of the Company has evaluated, with the participation of the Chief Executive Officer and Chief Financial Officer of the Company, the effectiveness of the Company’s disclosure controls and procedures (as defined in Rules 13a-15(e) or 15d-15(e) promulgated by the Securities and Exchange Commission pursuant to the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on that evaluation, the Chief Executive Officer and Chief Financial Officer of the Company had concluded that the Company’s disclosure controls and procedures as of the period covered by this Quarterly Report on Form 10-Q were effective.
   
  ii) Changes in internal control over financial reporting .
   
  Management of the Company has also evaluated, with the participation of the Chief Executive Officer of the Company, any change in the Company’s internal control over financial reporting that occurred during the period covered by this Quarterly Report on Form 10-Q and determined that there was no change in the Company’s internal control over financial reporting that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.

 

 

Chief Executive   Director

 

 

 

 12 

 

 

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND PLAN OF OPERATIONS

 

Forward-looking Statements

 

Except for statements of historical fact, the information presented herein constitutes forward-looking statements. These forward-looking statements generally can be identified by phrases such as “anticipates,” “believes,” “estimates,” “expects,” “forecasts,” “foresees,” “intends,” “plans,” or other words of similar import. Similarly, statements herein that describe our business strategy, outlook, objectives, plans, intentions or goals also are forward-looking statements.  Such forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited to, our ability to: successfully commercialize our technology; generate revenues and achieve profitability in an intensely competitive industry; compete in products and prices with substantially larger  and better capitalized competitors; secure, maintain and enforce a strong intellectual property portfolio; attract additional capital sufficient to finance our working capital requirements, as well as any investment of plant, property and equipment; develop a sales and marketing infrastructure; identify and maintain relationships with third party suppliers who can provide us a reliable source of raw materials; acquire, develop, or identify for our own use, a manufacturing capability; attract and retain talented individuals; continue operations during periods of uncertain general economic or market conditions, and; other events, factors and risks previously and from time to time disclosed in our filings with the Securities and Exchange Commission. Although we believe the expectations reflected in our forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. You should not place undue reliance on our forward-looking statements, which speak only as of the date of this report. Except as required by law, we do not undertake to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.

 

Overview

 

We were incorporated in the State of Nevada on June 6, 2007. On August 2, 2010, we changed our name from Bella Viaggio, Inc. to Kat Gold Holdings Corp. Effective January 1, 2015, we completed an exchange agreement to purchase 100% of the outstanding interests of REMSleep LLC in exchange for 50,000,000 common shares of REMSleep Holdings, Inc.’s stock, at which time REMSleep LLC became our wholly-owned subsidiary and adopted their business of developing and distributing our sleep apnea products. On January 5, 2015, we changed our name to REMSleep Holdings, Inc. to reflect our new business model.

 

Our officers have 35 years of sleep-industry experience, including having been employed at sleep industry companies. Our officers invented our DeltaWave CPAP interface (the “DeltaWave”) as an innovative new device to treat patients with sleep apnea. The patent-pending DeltaWave product is a nasal-pillows type interface that will result in better comfort and, therefore, better compliance since it was specifically designed with unique airflow characteristics to enable patients with sleep apnea to breathe normally. A survey that appeared in DME Business found that 89% of patients stated that mask-interface comfort was their primary concern. The primary issue that we have addressed with the DeltaWave is the “work of breathing” component. We believe that our DeltaWave is designed to effectively address the stubborn issues that continue to affect a patient’s ability to comply with treatment, as follows:

 

  Does not disrupt normal breathing mechanics;

 

  Is not claustrophobic;

 

  Causes zero work of breathing (WOB);

 

  Minimizes or eliminates drying of the sinuses;

 

  Uses less driving pressure; and

 

  Allows users to feel safe and secure while sleeping.

 

 

 

 13 

 

 

On June 28, 2016, we applied for a patent for a new, innovative sleep apnea product that serves as an interface for the delivery of CPAP therapy and other respiratory needs. Our goal is to develop sleep products that achieve optimum compliance and comfort for CPAP patients.

 

On April 27, 2021, Remsleep was awarded utility patent 10987481 for its new Deltawave CPAP Pillows Mask for delivery of CPAP therapy and other respiratory needs.  On March 5, 2024, Remsleep was awarded design patent D1,017,025 S.  Our goal is to continue to develop sleep products for the treatment of OSA and capture 10% of the market in the next 24 months.

 

Our website is located at: https://remsleep.com.

 

Results of Operations

 

The six months ended June 30, 2026 compared to the six months ended June 30, 2025

 

Revenues

 

We had no revenue for the six months ended June 30, 2026 and 2025.

 

Operating Expenses

 

Professional fees were $8,580 and $7,800 for the six months ended June 30, 2026 and 2025, respectively, an increase of $780 or 10.0%. Professional fees consist mostly of accounting, audit and legal fees.

 

Compensation expense was $29,700 and $27,000 for the six months ended June 30, 2026 and 2025, respectively, an increase of $2,700 or 10.0%. Compensation was paid to our former CEO and to Ms. Michaels and Mr. Marshall.

 

Development expenses were $0 and $17,200 for the six months ended June 30, 2026 and 2025, respectively, a decrease of $17,200. Our development expenses have decreased in the current period as we have completed the development and testing of our DeltaWave product.

 

Lease expenses were $6,200 and $24,891 for the six months ended June 30, 2026 and 2025, respectively, a decrease of $18,691 or 75.1%. In the current period we have a new, less expensive lease, in a new location.

 

General and administrative expenses (“G&A”) were $223,138 and $54,424 for the six months ended June 30, 2026 and 2025, respectively, an increase of $168,714 or 310.0%. Our largest G&A expenses in the current period consist principally of product expense and selling expense for payments to outside salespeople.

 

Other Expenses

 

The total other expense of $125,792 for the six months ended June 30, 2026, included $83,965 for interest expense and a loss on issuance of convertible debt of $94,454. These losses were partially offset by a $36,136 gain on conversion of debt and a $16,491 gain on the change in fair value of derivatives. The total other income of $45,827 for the six months ended June 30, 2025, included $76,332 for interest expense and a loss on the issuance of convertible debt of $85,867. These losses were offset by a $208,026 gain on the change in fair value of derivatives.

 

 

 

 14 

 

 

Net Loss

 

For the six months ended June 30, 2026, we had a net loss of $393,410 as compared to a net loss of $85,488 for the six months ended June 30, 2025. The $307,922 increase to our net loss is due to the reasons discussed above.

 

Liquidity and Capital Resources

 

Cash flow from operations

 

Cash used in operating activities for the six months ended June 30, 2026, was $418,377.

 

Cash Flows from Financing

 

For the six months ended June 30, 2026, we received $35,000 in cash from the issuance of convertible notes payable. Together with $80,420 attributable to common stock issued during the period, net cash provided by financing activities was $115,420.

 

Going Concern

 

As of June 30, 2026, there is substantial doubt regarding our ability to continue as a going concern as we have not generated sufficient cash flow from revenue to fund our proposed business.

 

We have suffered recurring losses from operations since our inception. In addition, we have yet to generate an internal cash flow from our business operations or successfully raised the financing required to develop our proposed business. As a result of these and other factors, our independent auditor has expressed substantial doubt about our ability to continue as a going concern. Our future success and viability, therefore, are dependent upon our ability to generate capital financing. The failure to generate sufficient revenues or raise additional capital may have a material and adverse effect upon us and our shareholders.

 

On or about June 1, 2026, the Company began implementing certain operational and administrative changes in connection with its transition plan under new management. The Company has closed its former office located in Georgia and has relocated its principal office operations to Florida. In connection with the relocation, the Company has also established a new warehouse facility in Florida to support its ongoing business operations located at 1900 6th Ave, South Lake Worth, FL 33461. The Company is transitioning its business model away from the prior retail “cash and carry” walk-in traffic model in the rural town of Blackshear, Georgia, toward a business model focused more heavily based on Internet e-commerce and e-retail sales channels such as eBay and similar e-tailers launching nationwide and then moving on to International markets.

 

Off Balance Sheet Arrangements

 

We have no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to investors.

 

Critical Accounting Policies

 

Refer to Note 2 to the Financial Statements for the six months ended June 30, 2026, for a discussion of our critical accounting policies and our Form 10-K for the year ended December 31, 2025, for a full discussion of our critical accounting policies and procedures.

 

 

 

 15 

 

 

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK.

 

We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and, as such, are not required to provide the information under this Item.

 

ITEM 4. CONTROLS AND PROCEDURES

 

Disclosure Controls and Procedures

 

Our principal executive officer and principal financial officer have evaluated the effectiveness of our disclosure controls and procedures, as defined in Rules 13a - 15(e) and 15d - 15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), as of the end of the period covered by this quarterly report. Based on their evaluation, each such person concluded that our disclosure controls and procedures were not effective as of March 31, 2026 due to a lack of segregation of duties.

 

In designing and evaluating disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable, not absolute assurance of achieving the desired objectives. Also, the design of a control system must reflect the fact that there are resource constraints and the benefits of controls must be considered relative to their costs.

 

Changes in Internal Control over Financial Reporting.

 

Our management has evaluated whether any change in our internal control over financial reporting occurred during the last fiscal quarter. Based on that evaluation, management concluded that there has been no change in our internal control over financial reporting during the relevant period that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

 

 

 

 

 

 16 

 

 

PART II - OTHER INFORMATION

 

ITEM 1. LEGAL PROCEEDINGS

 

None.

 

ITEM 1A. RISK FACTORS

 

We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and, as such, are not required to provide the information under this Item.

 

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

 

During the three months ended March 31, 2026, 1800 Diagonal converted $79,900 and $6,270 of principal and interest, respectively, into 35,419,997 shares of common stock.

 

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

 

None.

 

ITEM 4. MINE SAFETY DISCLOSURES

 

Not applicable.

 

ITEM 5. OTHER INFORMATION

 

The Company previously disclosed certain matters relating to changes in control, management changes, and compensatory arrangements in a Current Report on Form 8-K filed with the Securities and Exchange Commission on June 4, 2026. Such disclosures are incorporated herein by reference.

 

During the quarter ended June 30, 2026, no director or officer of the Company adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(a) of Regulation S-K.

 

ITEM 6. EXHIBITS

 

(a) Documents furnished as exhibits hereto:

 

Exhibit No.   Description
10.1 (1)   Convertible Promissory Note and Securities Purchase Agreement, Quick Capital LLC, January 27, 2026
31.1   Certification of the Chief Executive Officer and Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1   Certification pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
101.INS   Inline XBRL Instance Document
101.SCH   Inline XBRL Taxonomy Extension Schema Document
101.CAL   Inline XBRL Taxonomy Calculation Linkbase Document
101.DEF   Inline XBRL Taxonomy Extension Definition Linkbase Document
101.LAB   Inline XBRL Taxonomy Label Linkbase Document
101.PRE   Inline XBRL Taxonomy Presentation Linkbase Document
104   Cover Page Interactive Data File (formatted as Inline XBRL and contained in exhibit 101).

 

(1) Previously filed with Form 10-K on April 15, 2026.

 

 

 

 17 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

 

  REMSLEEP HOLDINGS, INC.
     
Date: August 14, 2026 By: /s/ Sanja Pekovic
    Sanja Pekovic
    Chief Executive Officer
(Principal Executive Officer)
(Principal Financial and Accounting Officer)

 

Date: August 14, 2026 By: /s/ Teresita Rubio
    Teresita Rubio
    Chairman of the Board

 

 

 

 

 

 

 

 

 18 

 


ATTACHMENTS / EXHIBITS

ATTACHMENTS / EXHIBITS

CERTIFICATION

CERTIFICATION

XBRL SCHEMA FILE

XBRL CALCULATION FILE

XBRL DEFINITION FILE

XBRL LABEL FILE

XBRL PRESENTATION FILE

IDEA: R1.htm

IDEA: R2.htm

IDEA: R3.htm

IDEA: R4.htm

IDEA: R5.htm

IDEA: R6.htm

IDEA: R7.htm

IDEA: R8.htm

IDEA: R9.htm

IDEA: R10.htm

IDEA: R11.htm

IDEA: R12.htm

IDEA: R13.htm

IDEA: R14.htm

IDEA: R15.htm

IDEA: R16.htm

IDEA: R17.htm

IDEA: R18.htm

IDEA: R19.htm

IDEA: R20.htm

IDEA: R21.htm

IDEA: R22.htm

IDEA: R23.htm

IDEA: R24.htm

IDEA: R25.htm

IDEA: R26.htm

IDEA: R27.htm

IDEA: R28.htm

IDEA: R29.htm

IDEA: R30.htm

IDEA: R31.htm

IDEA: R32.htm

IDEA: R33.htm

IDEA: R34.htm

IDEA: R35.htm

IDEA: R36.htm

IDEA: R37.htm

IDEA: FilingSummary.xml

IDEA: MetaLinks.json

IDEA: remsleep_i10q-063026_htm.xml